Evaxion BiotechEVAX
About: Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
Employees: 49
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
20% more capital invested
Capital invested by funds: $1.31M [Q2] → $1.57M (+$258K) [Q3]
17% more funds holding
Funds holding: 6 [Q2] → 7 (+1) [Q3]
0.04% more ownership
Funds ownership: 0.87% [Q2] → 0.91% (+0.04%) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 48 / 159 met price target | 759%upside $14 | Buy Reiterated | 1 Nov 2024 |
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 48 / 159 met price target | 759%upside $14 | Buy Reiterated | 26 Sept 2024 |
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 48 / 159 met price target | 759%upside $14 | Buy Reiterated | 20 Sept 2024 |
Financial journalist opinion
Based on 3 articles about EVAX published over the past 30 days
